Considerations regarding the use of blood samples in the proteomic identification of biomarkers for cancer diagnosis

Cancer Genomics and Proteomics

Volumn 3, Issue 3-4, 2006, Pages 227-230

  Sapan, Christine V ^a,b   Lundblad, Roger L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Biomarkers; Blood plasma; Proteomics; Review; Serum

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CALCIUM ION; CITRATE SODIUM; EDETIC ACID; HEPARIN; VASCULOTROPIN;

BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CANCER DIAGNOSIS; CENTRIFUGATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FRACTIONATION; HUMAN; PLASMA; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; STANDARDIZATION; STORAGE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VEIN PUNCTURE;

EID: 33746587519     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Gore M and Hered J: Pelvic mass in a woman over 40 years. In: Clinical Management of Ovarian Cancer. Ledermann JA, Hoskins WJ, Kaye SB and Vergote IB (eds.). London, Martin Dunitz, pp. 1-10, 2001.
2. Look KY: Epidemiology, etiology, and screening of ovarian cancer. In: Ovarian Cancer 2nd Edn. Rubin SC and Sutton GP (eds). Philadelphia, Lippincott, Williams & Wilkins, 167-180, 2001.
3. Bast RC Jr, Urban N Schridher V et al: Early detection of ovarian cancer: promise and reality. In: Ovarian Cancer. Stack MS and Fishman DA (eds.). Boston, Kluwer Academic Publishers, pp. 61-97, 2004.
4. Jacobs IJ and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355-366, 2005.
5. Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856, 2005.
6. Bast RC Jr, Knapp RC, Runowicz C et al: Use of the CA125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 19: 354-356, 1985.
7. Saksela E: Prognostic markers in epithelial ovarian cancer. Int J Gynecol Pathol 12: 156-161, 1993.
8. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
9. Strigley JR, Amin M, Boccon-Gibod L et al: Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives, Scand J Urol Nephrol Suppl 216L: 8-19, 2005.
10. Sharples LD: Statistical approaches to rational biomarker selection. In: Biomarkers in Disease. An Evidence-based Approach. Trull AK et al (eds.). Cambridge, Cambridge University Press, pp. 24-31, 2002.
11. McIntosh MW, Drescher C, Karlan B et al: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncology 95: 9-15, 2004.
12. Zhang Z, Bast RC Jr, Yu Y et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890, 2004.
13. Petersen PH, Sandberg S, Fraser CG and Goldschmidt H: Influence of index of individuality on false positives in repeated sampling from healthy individuals, Clin Chem Lab Med 39: 160-165, 2001.
14. Tuxen MK, Sölétormus G, Petersen PH, Schiøler V and Dombernowsky P: Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 74: 12-22, 1999.
15. Bjorhall K, Miliotis T and Davidsson P: Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5: 307-317, 2005.
16. Echan LA, Tang HY, Ali-khan N, Lee K and Speicher DW: Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5: 3292-3303, 2005.
17. Vitzhum F, Behren F, Anderson NL and Shaw JH: Proteomics: from basis research to diagnostic application. A review of requirements & needs. J Proteome Res 4: 1086-1097, 2005.
18. Granger J, Siddiqui J, Copeland S and Remick D: Albumin depletion of human plasma also removed low abundance proteins including the cytokines. Proteomics 5: 4713-4718, 2005.
19. Smolensky MH, Reinberg AE, Martin RJ and Haos E: Clinical chronobiology and chemotherapeutics with application to asthma. Chronobiol Int 16: 539-563, 1999.
20. Friedman RB and Young DS: Effects of Disease on Clinical Laboratory Tests, AACC Press, Washington DC, 1997.
21. Young DS: Effects of Drugs on Clinical Laboratory Tests, 5th edn. AACC Press, Washington, DC, 2000.
22. Koepke JA: Specimen collection - cellular hematology. In: Laboratory Hematology. Koepke JA (ed.)., Philadelphia, Churchill Livingstone, Vol. 2, pp. 821-831, 1984.
23. Budtz-Olsen OE: Clot Retraction. Springfield, IL, C.C. Thomas, Springfield, IL, 1951.
24. Kingdon HS and Lundblad RL: Factors affecting the evolution of factor XIa during blood coagulation J Lab Clin Med 55: 826-831, 1976.
25. Schneider DJ, Tracy PB, Mann KG and Sobel BE: Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 96: 2877-2883, 1997.
26. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D and Selby DJ: Influences of blood sample processing in low-molecular weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51: 1637-1649, 2005.
27. Tammen H, Schulte I, Hess R, Menzel C, Kellman M, Mohring T and Schultze-Knappe P: Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum specimens by differential peptide display. Proteomics 5: 3414-3422, 2005.
28. Faulk WP, Torny DS and McIntyre JA: Effects of serum versus plasma on agglutination of antibody-coated indicator cells by human rheumatoid factor. Clin Immunol Immunopathol 46: 169-176, 1988.
29. Lum G and Gambino SR: A comparison of serum versus heparinized plasma for routine clinical tests. Amer J Clin Pathol 61: 108-113. 1974.
30. Ladenson JH, Tsai L-M, Michael JM, Kessler G and Joist JH: Serum versus heparinized plasma for eighteen common chemistry tests. Amer J Clin Pathol 62: 545-552, 1974.
31. Benoy I, Salgado R, Colpaert C et al: Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2: 311-315, 2002.
32. Spence GM, Graham AN, Mulholland K et al: Vascular endothelial growth factor levels in serum and platelets following esophageal cancer resection - relationship to platelet count. Int J Biol Markers 17: 119-124, 2002.
33. Boyanton BL Jr and Blick KE: Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 48: 2242-2247, 2002.
34. Preissner CM, Reilly WM, Cyr RC et al: Plastic versus glass tubes: Effects on analytical performance of selected serum and plasma hormone assays. Clin Chem 50: 1245-1246, 2004.
35. Evans MJ, Livesey JH, Ellis MJ and Yandle TO: Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 34: 107-112, 2001.
36. Prisco D, Panicca R, Bandinelli B et al: Euglobulin lysis time in fresh and stored samples. Amer J Clin Pathol 102: 794-796, 1994.
37. Guder WG: Who cares about the stability of analytes? Eur J Clin Chim Biochem 33: 177, 1995.
38. Heins M, Heil W and Withold W: Storage of serum or whole blood samples? Effects of time and temperature on 22 serum analytes. Eur J Clin Chem Biochem 33: 231-238, 1995.
39. Qvist P, Munk M, Hoyle N and Christianen C: Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 350: 167-173, 2004.
40. Kioukia-Fouglia N, Christofidis I and Strantzalis N: Physicochemical conditions affecting the formation/stability of serum complexes and the determination of prostate-specific antigen (PSA). Anticancer Res 19: 3315-3320, 1999.